The effects of Acanthopanax senticosus polysaccharide (ASP) on antioxidant status had been investigated both in vitro and in alloxan-induced diabetic mice. In vitro antioxidant assays, ASP had a potent scavenging ability to superoxide radical and hydroxyl radicals. In vivo experiment, male Wistar rats were made diabetic by injection of alloxan and ASP (50, 100 and 200 mg/kg) was administered to diabetic mice for two months. ASP treatment could significantly and dose-dependently reduce the levels of lipid peroxidation markers, namely thiobarbituric acid reactive substances (TBARS) and lipid hydroperoxides (LP), and elevate enzymic antioxidants, such as superoxide dismutase (SOD) and catalase (CAT) activities in the plasma, liver, kidney and heart of diabetic rats. Moreover, increased level of serum insulin and decreased level of blood glucose (FBG) were observed in the plasma of diabetic control rats. The results demonstrated that ASP oral administration had an efficacious amelioration effect on the antioxidant status in alloxan-induced diabetic mice.Highlights► A homogeneous polysaccharide (ASP) was extracted from Acanthopanax senticosus. ► ASP had a potent scavenging ability to superoxide radical and hydroxyl radicals in vitro. ► ASP could reduce the levels of TBARS and LP in diabetic mice. ► ASP could elevate SOD and CAT activities of diabetic rats. ► ASP could decrease the level of FBG and increase the level of FINS.

FAT10, as a small ubiquitin-like modifier, plays an important role in various cellular processes, including mitosis, immune response, and apoptosis, the dys-regulation of which may arise tumorigenesis. Therefore, the aim of this study was to examine the expression of FAT10 at gene and protein levels in glioma samples with different WHO grades and its association with survival. One hundred and twenty-eight glioma specimens and 10 non-neoplastic brain tissues were collected. Immunohistochemistry assay, quantitative real-time PCR and Western blot analysis were carried out to investigate the expression of FAT10. Kaplan-Meier method and Cox’s proportional hazards model were used in survival analysis. Immunohistochemistry showed that FAT10 protein was over-expressed in glioma tissues. FAT10 mRNA and protein levels were both higher in glioma compared to control on real-time PCR and Western blot analysis (both P < 0.001). Additionally, its expression levels increase from grade I to grade IV glioma according to the results of real-time PCR, immunohistochemistry analysis and Western blot. Moreover, the survival rate of FAT10-positive patients was significantly lower than that of FAT10-negative patients (P < 0.001). We further confirmed that the increased expression of FAT10 was a significant and independent prognostic indicator in glioma by multivariate analysis (P < 0.001). Our data provides convincing evidence for the first time that the increased expression of FAT10 at gene and protein levels is correlated with poor outcome in patients with glioma. FAT10 may promote the aggressiveness of glioma and may be a potential prognosis predictor of glioma.